Camp4 Therapeutics Corp

CAMP Nasdaq SEC CIK 1736730
Follow Camp4 Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.9M +138.9% vs same quarter last year
Net income −$29M −91.8% vs same quarter last year
EPS, diluted −$0.37 +32.7% vs same quarter last year
Operating cash flow −$8.2M +27.2% vs same quarter last year
Revenue by quarter
$652K
$858K
$1.5M
$795K
$348K
$1.3M
$1.8M
$1.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
  • Revenue
  • Net income
−$100M−$75M−$50M−$25M$0$25MFY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$3.5M−$80.4M
FY24$652K−$51.8M
FY23$350K−$49.3M
FY22--
MarginsShare of revenue
  • Operating margin
  • Net margin
−15000%−10000%−5000%0%FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−1502.4%−2298.5%
FY24−8142.3%−7943.4%
FY23−14822.6%−14083.1%
FY22--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$29.8M
FY24−$46M
FY23−$44.8M
FY22-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Camp4 Therapeutics
  • Healthcare median
−15000%−10000%−5000%0%FY22FY23FY24FY25
Show the numbers
YearCamp4 TherapeuticsHealthcare median
FY25−2298.5%−30.6%
FY24−7943.4%−47%
FY23−14083.1%−58%
FY22-−80.4%